Ascendis Pharma A/S (ASND) Scheduled to Post Quarterly Earnings on Thursday

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) is scheduled to be announcing its earnings results on Thursday, April 25th.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.15) by $0.49. The company had revenue of $148.62 million for the quarter, compared to analyst estimates of $97.02 million. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative return on equity of 16,574.15%. On average, analysts expect Ascendis Pharma A/S to post $-4 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ascendis Pharma A/S Stock Performance

NASDAQ:ASND traded down $1.65 during trading hours on Wednesday, reaching $143.18. The company's stock had a trading volume of 244,223 shares, compared to its average volume of 368,340. The company has a market capitalization of $8.34 billion, a P/E ratio of -15.48 and a beta of 0.50. The stock has a 50 day moving average price of $149.15 and a two-hundred day moving average price of $125.48. Ascendis Pharma A/S has a 12 month low of $66.03 and a 12 month high of $161.00.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ASND. Wedbush upped their price objective on Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an "outperform" rating in a research note on Thursday, February 8th. Wells Fargo & Company raised their price target on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the company an "overweight" rating in a report on Friday, March 15th. Cantor Fitzgerald reiterated an "overweight" rating and set a $173.00 price objective on shares of Ascendis Pharma A/S in a research note on Thursday, April 18th. Morgan Stanley restated an "equal weight" rating and issued a $116.00 target price on shares of Ascendis Pharma A/S in a research note on Monday. Finally, JPMorgan Chase & Co. upped their price target on Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an "overweight" rating in a research report on Tuesday, April 2nd. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $173.25.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.